Business
Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases
Company prioritizes ophthalmology pipeline programs with potential to provide new or improved treatment options in multiple severe and disabling eye diseases Announces an oversubscribed financing of $175 million in gross proceeds, which funds multiple ophthalmology programs through phase 1 safety, tolerability and efficacy studies Company discontinues clinical development of SZN-043 in severe alcohol associated hepatitis SOUTH SAN FRANCISCO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Surrozen, I
About this update from Surrozen, Inc.
[{"type":"image","alt":"Surrozen, Inc.","displaySize":"","headline":null,"caption":"Surrozen, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":1280,"height":720,"url":"https://ml.globenewswire.com/Resource/Download/1402e192-4e1a-498f-b1b0-f8858e4d4858?size=2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/x6DV722PrEWTqtVALzIaoQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://ml.globenewswire.com/Resource/Download/1402e192-4e1a-498f-b1b0-f8858e4d4858?size=2","width":960,"height":540},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/_Nw2ZiUnSxKs.uMojTysxg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xMzUwO2NmPXdlYnA-/https://ml.globenewswire.com/Resource/Download/1402e192-4e1a-498f-b1b0-f8858e4d4858?size=2","width":1200,"height":675}},"lazy":false},{"type":"text","content":"Company prioritizes ophthalmology pipeline programs with potential to provide new or improved treatment options in multiple severe and disabling eye diseases","length":157,"tagName":"p"},{"type":"text","content":"Announces an oversubscribed financing of $175 million in gross proceeds, which funds multiple ophthalmology programs through phase 1 safety, tolerability and efficacy studies","length":174,"tagName":"p"},{"type":"text","content":"Company discontinues clinical development of SZN-043 in severe alcohol associated hepatitis","length":91,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt Pathway for tissue repair and regeneration, today announced that the company will focus its Wnt biology expertise and Wnt signal modulation antibody technologies on its ophthalmology programs including development of new treatment options for retinopathies. The Company also announced a private placement consisting of two tranches in aggregate up to $175 million in gross proceeds to fund multiple ophthalmology programs through initial Phase 1 safety, tolerability and efficacy studies.","length":695,"tagName":"p"},{"type":"text","content":"Modulation of Wnt signaling has the potential to be relevant in a broad range of highly prevalent eye diseases including “wet” and “dry” Age Related Macular Degeneration (AMD), diabetic retinopathy, Fuchs’ endothelial corneal dystrop...